Fletcher led the index higher as building consents point to increased activity.
Company shares plummeted in August after company said Cxbladder tests would no longer qualify for reimbursement under proposed changes.
Delays in US registration of Maxigesic IV has deferred licence income.
The hospitality business fell victim to Covid-19 and rising costs but was trading well in recent months.
NZX-listed insurer’s results announcement was delayed by ‘miserable glitch’.
Oceania Healthcare says focus on premium care suites is paying off.
Booking volumes continue to rise, but net loss widens.
Smartshares approaching $10b in funds under management under $31.25m acquisition.
Pent-up demand for used cars drives half-year revenue.
Interim revenue of $91 million is ahead of this time last year.
